Biology of Blood and Marrow Transplantation
Volume 12, Issue 8 , Pages 795-807 , August 2006

Role of Allogeneic Stem Cell Transplantation for Adult Chronic Myeloid Leukemia in the Imatinib Era

  • Andrew Grigg

      Affiliations

    • Department of Clinical Haematology and Bone Marrow Transplantation, Royal Melbourne Hospital, Melbourne, Australia
    • Corresponding Author InformationCorrespondence and reprint requests: Andrew Grigg, Associate Professor, C/- Haematology Department, The Royal Melbourne Hospital, Grattan Street, Parkville, Victoria, 3050, Australia.
    • ,
  • Timothy Hughes

      Affiliations

    • Department of Haematology, Institute of Medical and Veterinary Science, Adelaide, Australia

Received 6 January 2006 ,Accepted 29 March 2006.

References 

  1. Radich JP , Gooley T , Bensinger WC , et al.   HLA-matched related hematopoietic cell transplantation for chronic phase CML using a targeted busulfan and cyclophosphamide preparative regimen . Blood . 2003;102:31–35
  2. Goldman JM , Rizzo JD , Sobocinski KA , et al.   Long-term outcome after allogeneic stem cell transplantation for CML . [abstract]. Hematol J. . 2004;5:S89–S109 Abstract 266.
  3. Higano CS , Chielens D , Raskind W , et al.   Use of α-2a-interferon to treated cytogenetic relapse of chronic myeloid leukemia after marrow transplantation . Blood . 1997;90:2554–2954
  4. Mackinnon S . Who may benefit from donor leucocyte infusions after allogeneic stem cell transplantation? . Br J Haematol. . 2000;110:2–17
  5. Kantarjian HM , O’Brien S , Cortes JE , et al.   Imatinib mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemia . Blood . 2002;100:1590–1595
  6. DeAngelo DJ , Hochberg EP , Alyea EP , et al.   Extended follow-up of patients treated with imatinib mesylate (Gleevec) for chronic myelogenous leukemia relapse after allogeneic transplantation (durable cytogenetic remission and conversion to complete donor chimerism without graft versus host disease) . Clin Cancer Res. . 2004;10:5065–5071
  7. Hess G , Bunjes D , Siegert W , et al.   Sustained complete molecular remissions after treatment with imatinib-mesylate in patients with failure after allogeneic stem cell transplantation for chronic myelogenous leukemia (results of a prospective phase II open-label multicenter study) . J Clin Oncol. . 2005;23:7583–7593
  8. Olavarria E , Kanfer E , Szydlo R , et al.   Early detection of BCR-ABL transcripts by quantitative reverse transcriptase-polymerase chain reaction predicts outcome after allogeneic stem cell transplantation for chronic myeloid leukemia . Blood . 2001;97:1560–1565
  9. Weisdorf DJ , Anasetti C , Antin JH , et al.   Allogeneic bone marrow transplantation for chronic myelogenous leukemia, comparative analysis of unrelated versus matched sibling donor transplantation . Blood . 2002;99:1971–1977
  10. Mickelson E , Petersdorf E , Hansen J . HLA matching and hematopoietic cell transplant outcome . Clin Transpl. . 2002;263–271
  11. Hansen JA , Gooley TA , Martin PJ , et al.   Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia . N Engl J Med. . 1998;338:962–968
  12. Gratwohl A , Hermans J , Goldman JM , et al.   Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation . Lancet . 1998;352:1087–1092
  13. Passweg JR , Walker I , Sobocinski KA , et al.   Validation and extension of the EBMT risk score for patients with chronic myeloid leukaemia (CML) receiving allogeneic haematopoietic stem cell transplants . Br J Haematol. . 2004;125:613–620
  14. Clift RA , Radich J , Appelbaum FR , et al.   Long term follow-up of a randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide for patients receiving allogeneic marrow transplants during chronic phase of chronic myeloid leukemia . Blood . 1999;44:3960–3962
  15. Elmaagacli AH , Beelen DW , Opalka B , et al.   The risk of residual molecular and cytogenetic disease in patients with Philadelphia-chromosome positive first chronic phase chronic myelogenous leukemia is reduced after transplantation of allogeneic peripheral blood stem cells compared with bone marrow . Blood . 1999;94:384–389
  16. Oehler VG , Radich JP , Storer B , et al.   Randomized trial of allogeneic related bone marrow transplantation versus peripheral blood stem cell transplantation for chronic myeloid leukemia . Biol Blood Marrow Transplant. . 2005;11:85–92
  17. Stem Cell Trialists’ Collaborative Group . Allogeneic peripheral blood stem-cell compared with bone marrow transplantation in the management of hematologic malignancies, an individual patient data meta-analysis of nine randomized trials . J Clin Oncol. . 2005;23:5074–5087
  18. Chiodi S , Spinelli S , Ravera G , et al.   Quality of life in 244 recipients of allogeneic bone marrow transplantation . Br J Haematol. . 2000;110:614–619
  19. Gratwohl A , Brand R , Apperley J , et al.   Graft-versus-host disease and outcome in HLA-identical sibling transplantations for chronic myeloid leukemia . Blood . 2002;100:3877–3886
  20. Or R , Shapira MY , Resnick I , et al.   Nonmyeloablative allogeneic stem cell transplantation for the treatment of chronic myeloid leukemia in first chronic phase . Blood . 2003;101:441–445
  21. Mielcarek M , Martin PJ , Leisenring W , et al.   Graft versus host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation . Blood . 2003;102:756–762
  22. Kerbauy FR , Storb R , Hegenbart U , et al.   Hematopoietic cell transplantation from HLA-identical sibling donors after low-dose radiation-based conditioning for treatment of CML . Leukemia. . 2005;19:990–997
  23. Sloand E , Childs RW , Solomon S , et al.   The graft versus leukemia effect of nonmyeloablative stem cell allografts may not be sufficient to cure chronic myelogenous leukemia . Bone Marrow Transplant. . 2003;32:897–901
  24. Crawley C , Szydio R , Lalancette M , et al.   Outcomes of reduced-intensity transplantation for chronic myeloid leukemia (an analysis of prognostic factors from the chronic leukemia working party of the EBMT) . Blood . 2005;106:2969–2976
  25. Carella M , Lerma E , Corsetti MT , et al.   Autografting with Philadelphia chromosome negative mobilized hematopoietic progenitor cells in chronic myelogenous leukemia . Blood . 1999;93:1534–1539
  26. Koziner B , Dengra C , Lucero G , et al.   Autologous stem cell transplantation for patients with chronic myeloid leukemia . Cancer . 2002;95:2339–2345
  27. Hui CH , Goh KY , White D , et al.   Successful peripheral blood stem cell mobilisation with filgrastim in patients with chronic myeloid leukaemia achieving complete cytogenetic response with imatinib, without increasing disease burden as measured by quantitative real-time PCR . Leukemia. . 2003;17:821–828
  28. Simonsson B . Beneficial effects of cytogenetic and molecular response on long-term outcome in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib (IM) (update from the IRIS Study) . [abstract] Blood . 2005;106:166
  29. Branford S , Rudzki Z , Grigg A , et al.   BCR-ABL levels continue to decrease up to 42 months after commencement of standard dose imatinib in patients with newly diagnosed chronic phase CML who achieve a major molecular response . [abstract] Blood . 2004;104:279
  30. Branford S , Rudzki Z , Grigg A , et al.   The frequency of detection of BCR-ABL mutations in imatinib treated patients with chronic phase CML who attain a complete cytogenetic response (CCR) does not diminish with increasing duration of CCR but the associated loss of response is usually gradual . [abstract] Blood . 2004;104:273
  31. Kantarjian HM , Talpaz M , O’Brien S , et al.   High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia . Blood . 2004;103:2873–2878
  32. Hughes T , Branford S , Reynolds J , et al.   Higher dose imatinib (600mg/day) with selective intensification in newly diagnosed CML patient in chronic phase; cytogenetic response rates at 12 months are superior to IRIS . [abstract] Blood . 2004;104:1001
  33. Anstrom KJ , Reed SD , Allen AS , et al.   Long term survival estimates for imatinib versus interferon-α plus low-dose cytarabine for patients with newly diagnosed chronic-phase chronic myeloid leukemia . Cancer . 2004;101:2584–2592
  34. Lange T , Bumm T , Mueller M , et al.   Durability of molecular remission in chronic myeloid leukemia patients treated with imatinib vs allogeneic stem cell transplantation . Leukemia. . 2005;19:1262–1265
  35. Graham SM , Jergensen HG , Allan E , et al.   Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro . Blood . 2002;99:319–325
  36. Holtz MS , Bhatia R . Effect of imatinib mesylate on chronic myelogenous leukemia hematopoietic progenitor cells . Leuk Lymphoma. . 2004;45:237–245
  37. Medina J , Kantarjian H , Talpaz M , et al.   Chromosomal abnormalities in Philadelphia chromosome-negative metaphases appearing during imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase . Cancer . 2003;98:1905–1911
  38. O’Shea D , Crotty G , Carroll P , et al.   Clonal karyotypic abnormalities in Philadelphia negative cells of CML patients treated with imatinib, is it under-reported and does it have any clinical significance? . Br J Haematol. . 2004;127:360–369
  39. Kovitz GA , Kantarjian HM , Garcia-Manero G , et al.   Secondary leukemia after imatinib mesylate (IM) therapy for chronic myelogenous leukemia (CML) . [abstract] Blood . 2005;106:4862
  40. Hayden PJ , Keogh F , NiConghaile M , et al.   A single centre assessment of long term quality of life status after sibling allogeneic stem cell transplantation for chronic myeloid leukaemia in first chronic phase . Bone Marrow Transplant. . 2004;34:545–556
  41. Hahn EA , Glendenning GA , Sorensen MV , et al.   Quality of life in patients with newly diagnosed chronic phase chronic myeloid leukemia on imatinib versus interferon alfa plus low-dose cytarabine (results from the IRIS study) . J Clin Oncol. . 2003;21:2138–2146
  42. Grimison P , Goldstein D , Schneeweiss J , et al.   Corticosteroid-responsive interstitial pneumonitis related to imatinib mesylate with successful rechallenge, and potential causative mechanisms . Int Med J. . 2005;35:136–139
  43. Sanchez-Gonzalez B , Pascual-Ramirez JC , Fernandez-Abellan P , et al.   Severe skin reaction to imatinib in a case of Philadelphia-positive acute lymphoblastic leukemia . Blood . 2003;101:2446
  44. Pou M , Saval N , Vera M , et al.   Acute renal failure secondary to imatinib mesylate treatment in chronic myeloid leukemia . Leuk Lymphoma. . 2003;44:1239–1241
  45. Lin NU , Sarantopoulos S , Stone JR , et al.   Fatal hepatic necrosis following imatinib mesylate therapy . Blood . 2003;102:3455–3456
  46. Breccia M , D’Elia GM , D’Andrea M , et al.   Pleural-pericardic effusion as uncommon complication in CML patients treated with imatinib . Eur J Haematol. . 2005;74:89–90
  47. Barton JC , Jones SC , Lamberth WC , et al.   Cardiac tamponade associated with imatinib mesylate therapy of chronic myelogenous leukemia . Am J Hematol. . 2002;71:139–140
  48. Ebnoether M , Stenoft J , Ford J , et al.   Cerebral oedema as a possible complication of treatment with imatinib . Lancet . 2002;359:1751–1752
  49. Esmaeli B , Pireto VG , Butler CE , et al.   Severe periorbital edema secondary to STI571 (Gleevec) . Cancer . 2001;95:881–887
  50. Grigg AP , Szer J , Zajac J , McClachlan R . Reproductive status in long term bone marrow transplant survivors receiving busulfan-cyclophosphamide (120mg/kg) . Bone Marrow Transplant. . 2002;6:1089–1095
  51. Seshadri T , McArthur GA , Seymour JF . Oligospermia in a patient receiving imatinib therapy for the hypereosinophilic syndrome . N Engl J Med. . 2004;351:2134–2135
  52. Hensley ML , Ford JM . Imatinib treatment (specific issues related to safety, fertility and pregnancy) . Semin Hematol. . 2003;40:21–25
  53. Ault P , Kantarjian H , O’Brien S , et al.   Pregnancy among patients with chronic myeloid leukemia treated with imatinib . J Clin Oncol. . 2006;24:1204–1208
  54. Choudhary DR , Mishra P , Kumar R , et al.   Pregnancy on imatinib (fatal outcome with meningocele) . Ann Oncol. . 2006;17:178–179
  55. O’Brien SG , Guilhot F , Larson RA , et al.   Imatinib compared with interferon and low dose cytarabine for newly diagnosed chronic phase chronic myeloid leukemia . N Engl J Med. . 2003;348:994–1004
  56. Hughes TP , Kaeda J , Branford S , et al.   Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia . N Engl J Med. . 2003;349:1421–1430
  57. White D , Saunders V , Lyons AB , et al.   In-vitro sensitivity to imatinib-induced inhibition of ABL kinase activity is predictive of molecular response in de-novo CML patients . Blood . 2005;206:2520–2526
  58. Huntly BJP , Giulhot F , Reid AG , et al.   Imatinib improves but may not fully reverse the poor prognosis of patients with CML with derivative chromosome 9 deletions . Blood . 2003;102:2205–2212
  59. Quintas-Cardama A , Kantarjian H , Talpaz M , et al.   Imatinib mesylate therapy may overcome the poor prognostic significance of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia . Blood . 2005;105:2281–2286
  60. Lundan T , Volin L , Ruutu T , et al.   Allogeneic stem cell transplantation reverses the poor prognosis of CML patients with deletions in derivative chromosome 9 . Leukemia. . 2005;19:138–140
  61. Deininger MW . Chronic myeloid leukaemia (management of early stage disease) . Hematology . 2005;174–182
  62. Guilhot F . Sustained durability of response plus high rates of cytogenetic responses result in long-term benefit for newly diagnosed chronic-phase chronic myeloid leukemia (CML-CP) treated with imatinib (IM) therapy (update from the IRIS study) . [abstract] Blood . 2004;104:21
  63. Kantarjian HM , Talpaz M , O’Brien S , et al.   Dose escalation of imatinib mesylate can overcome resistance to standard dose therapy in patients with chronic myelogenous leukemia . Blood . 2003;101:473–475
  64. Marin D , Goldman JM , Olavaria E , et al.   Transient benefit only from increasing the imatinib dose in CML patients who do not achieve complete cytogenetic remissions on conventional doses . Blood . 2003;102:2702–2703
  65. Zonder JA , Pemberton P , Brandt H , et al.   The effect of dose increase of imatinib mesylate in patients with chronic or accelerated phase chronic myelogenous leukemia with inadequate hematologic or cytogenetic response to initial treatment . Clin Cancer Res. . 2003;9:2092–2097
  66. Branford S , Rudzki Z , Parkinson I , et al.   Real time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations . Blood . 2004;104:2926–2932
  67. Hochhaus A , Ernst T , Erben P , et al.   Long term observation of CML patients after imatinib resistance associated with BCR-ABL mutations . [abstract] Blood . 2005;106:1086
  68. Gore ME , Mohammed M , Ellwood K , et al.   Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification . Science . 2001;293:876–880
  69. Jabbour E , Cortes J , Talpaz M , et al.   Correlation of clinical response to dasatinib (BMS-354825) with BCR-ABL mutation status in imatinib-resistant patients (pts) which chronic myeloid leukemia (CML) treated at MD Anderson Cancer Center (MDACC) . [abstract] Blood . 2005;106:1091
  70. Branford S , Rudzki Z , Walsh S , et al.   Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis . Blood . 2003;102:276–283
  71. Corbin AS , La Rosee P , Stoffregen EP , et al.   Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib . Blood . 2003;101:4611–4614
  72. Soverini S , Martinelli G , Rosti G , et al.   ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival, a study by the GIMEMA Working Party on chronic myeloid leukemia . J Clin Oncol. . 2005;23:4100–4107
  73. Shah NP , Tran C , Lee FY , et al.   Overriding imatinib resistance with a novel ABL kinase inhibitor . Science . 2004;305:399–401
  74. Sawyers CL , Kantarjian H , Shah N , et al.   Dasatinib (BMS-354825) in patients with chronic myeloid leukemia (CML) and Philadelphia-chromosome positive acute lymphoblastic leukemia (PH+ ALL) who are resistant or intolerant to imatinib (update of a phase 1 study) . [abstract] Blood . 2005;106:38
  75. Branford S , Hughes T , Nicoll J , et al.   Major molecular responses to dasatinib (BMS-354825) are observed in imatinib-resistant late stage chronic and advanced CML patients (impact and fate of imatinib-resistant clones in dasatinib-treated patients) . [abstract] Blood . 2005;106:437
  76. Copland M , Hamilton A , Baird JW , et al.   Dasatinib (BMS-354825) has increased activity against bcr-abl compared to imatinib in primary CML cells in vitro, but does not eradicate quiescent CML stem cells . [abstract] Blood . 2005;106:695
  77. Kantarjian HM , Ottman O , Cortes J , et al.   AMN107, a novel aminopyrimidine inhibitor of bcr-abl, has significant activity in imatinib-resistant chronic myeloid leukemia (CML) or Philadelphia-chromosome-positive acute lymphoid leukemia (Ph+ ALL) . [abstract] Blood . 2005;106:37
  78. Oehler VG , Gooley T , Snyder DS , et al.   A retrospective study of patients treated with imatinib mesylate prior to allogeneic hematopoietic stem cell transplant . [abstract] Blood . 2004;104:2752
  79. Kantarjian HM , Cortes J , O’Brien S , et al.   Long-term survival Benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia after failure of interferon-α . Blood . 2004;104:1979–1988
  80. Marin D , Marktel S , Szydlo R , et al.   Survival of patients with chronic-phase chronic myeloid leukaemia on imatinib after failure on interferon alfa . Lancet . 2003;362:617–619
  81. Matsui W , Angstreich GR , Vala MS , et al.   Chronic myeloid leukemia stem cells and their differentiated progeny display divergent drug sensitivities to imatinib mesylate and interferon-alpha . [abstract] Blood . 2004;104:1996
  82. Marin D , Kaeda JS , Andreasson C , et al.   Phase I/II trial of adding semisynthetic homoharringtonine in chronic myeloid leukemia patients who have achieved partial or complete cytogenetic response on imatinib . Cancer . 2005;103:1850–1855
  83. Petersdorf EW , Kollman C , Hurley CK , et al.   Effect of HLA class II gene disparity on clinical outcome in unrelated donor hematopoietic cell transplantation for chronic myeloid leukemia (the US national marrow donor program experience) . Blood . 2001;98:2922–2929
  84. Kollman C , Howe CWS , Anasetti C , et al.   Donor characteristics as risk factors in recipients after transplantation of bone marrow from unrelated donors (the effect of donor age) . Blood . 2001;98:2043–2051
  85. Druker BJ , Gathmann I , Bolton AE , et al.   Probability and impact of obtaining a cytogenetic response to imatinib as initial therapy for chronic myeloid leukemia (CML) in chronic phase . [abstract] Blood . 2003;102:634
  86. Alyea EP , Kim HT , Ho V , et al.   Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of age . Blood . 2005;105:1810–1814
  87. Kantarjian H , Talpaz M , O’Brien S , et al.   Survival benefit with imatinib mesylate therapy in patients with accelerated-phase chronic myelogenous leukemia – comparison with historic experience . Cancer . 2005;103:2099–2108
  88. Talpaz M , Silver RT , Druker BJ , et al.   Imatinib induces durable haematological and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia (results of a phase 2 study) . Blood . 2005;89:1928–1937
  89. O’Dwyer ME , Mauro MJ , Kurilik G , et al.   The impact of clonal evolution on response to imatinib mesylate (STI571) in accelerated phase CML . Blood . 2002;100:1628–1633
  90. Sawyers CL , Hochhaus A , Feldman E , et al.   Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis (results of a phase II study) . Blood . 2002;99:3530–3538
  91. Kantarjian HM , Cortes J , O’Brien S . Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase . Blood . 2002;99:3547–3553
  92. Visani G , Rosti G , Bandini G , et al.   Second chronic phase before transplantation is crucial for improving survival of blastic phase chronic myeloid leukaemia . Br J Haematol. . 2000;109:722–728
  93. Gale RP , Horowitz MM , Ash RC . Identical-twin bone marrow transplants for leukemia . Ann Intern Med. . 1994;120:646–652
  94. Adams KM , Holmberg LA , Leisenring W , et al.   Risk factors for syngeneic graft versus host disease after adult hematopoietic cell transplantation . Blood . 2004;104:1894–1897
  95. Kim DW , Chung YJ , Lee S , et al.   Pretransplant imatinib can improve the outcome of nonmyeloablative stem cell transplantation without increasing the morbidity in Philadelphia chromosome positive chronic myeloid leukemia . Leukemia. . 2004;18:1907–1909
  96. Champlin R , Ghosh S , McCormick G , et al.   Sequential treatment with reduced intensity allogeneic stem cell transplantation and imatinib for chronic myelogenous leukemia (CML) . [abstract] Blood . 2004;104:812

PII: S1083-8791(06)00293-X

doi: 10.1016/j.bbmt.2006.03.012

Biology of Blood and Marrow Transplantation
Volume 12, Issue 8 , Pages 795-807 , August 2006

Article Tools

* Image Usage & Resolution